Short- (30-90 days) and mid-term (1-3 years) outcomes and prognostic factors of patients with esophageal cancer undergoing surgical treatments

Table 2 Treatment related information (n = 307)

Variables	Median (range) / n (%)
Tumor location
Upper	15 (4.9%)
Middle to upper	21 (6.8%)
Middle	171 (55.7%)
Middle to lower	43 (14.0%)
Lower	57 (18.6%)
Tumor diameter (cm)	3 (0, 10)
T stage
Tis	30 (9.8%)
1a	4 (1.3%)
1b	69 (22.5%)
2	75 (24.4%)
3	91 (29.6%)
4a	36 (11.7%)
4b	2 (0.7%)
N stage
0	215 (70.0%)
1	61 (19.9%)
2	28 (9.1%)
3	3 (1.0%)
G stage
0	30 (9.8%)
1	21 (6.8%)
1-2	73 (23.8%)
2	148 (48.2%)
2-3	24 (7.8%)
3	11 (3.6%)
pTNM
0	30 (9.8%)
I	108 (35.2%)
II	71 (23.1%)
III	87 (28.3%)
IVA	11 (3.6%)
Pathological type
Squamous cell carcinoma	268 (87.3%)
Intraepithelial neoplasia	30 (9.8%)
Adenocarcinoma	8 (2.6%)
Signet-ring cell carcinoma	1 (0.3%)
Neoadjuvant radiotherapy and/or chemotherapy	51 (16.6%)
Surgery
Mediastinoscopy/ laparoscopy/thoracoscopy	258 (84.0%)
Thoracotomy/laparotomy	27 (8.8%)
Endoscopic submucosal dissection	22 (7.2%)
Resection
R0	304 (99.0%)
R1	3 (1.0%)
Operation time (min)	270 (36, 485)
Intraoperative blood loss (mL)	150 (2, 1000)
Lymph node dissection	283 (92.2%)
Postoperative treatment
None	213 (69.4%)
Radiotherapy alone	7 (2.3%)
Chemotherapy alone	77 (25.1%)
Radiotherapy + chemotherapy	10 (3.3%)
Number of metastatic lymph nodes	0 (0, 8)